Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses

Cephalalgia

Volumn 17, Issue 4, 1997, Pages 541-550

  Moore, K H P ^a   Hussey, E K ^a   Shaw, S ^a   Fuseau, E ^b   Duquesnoy, C ^b   Pakes, G E ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Intranasal absorption; Pharmacokinetics; Safety; Sumatriptan; Tolerability

Indexed keywords

PLACEBO; SUMATRIPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; NORMAL HUMAN; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; VOLUNTEER;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PLACEBOS; REFERENCE VALUES; SEROTONIN AGONISTS; SUMATRIPTAN; VASOCONSTRICTOR AGENTS;

EID: 0030981544     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1997.1704541.x     Document Type: Article

References (23)

1. Humphrey PPA, Feniuk W. Mode of action of the antimigraine drug sumatriptan. Trends Pharmacol Sci 1991;12:444-6
2. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-5
3. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-21
4. Goadsby PJ, Zagami AS, Donnan GA, et al. Oral sumatriptan in acute migraine. Lancet 1991;338:782-3
5. The Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991;31:306-13
6. Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994;241:138-44
7. Data on file, Glaxo Wellcome Inc.
8. Salonen R, Ashford E, Dahlöf C, et al. Intranasal sumatriptan for the acute treatment of migraine. J Neurol 1994;241:463-9
9. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol 1991;31:332-8
10. Duquesnoy C, Mamet JP, Sumner D, Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Submitted to Journal of Pharmaceutical Sciences
11. Andrew PD, Birch HL, Phillpot DA. Determination of sumatriptan succinate in plasma and urine by high-performance liquid chromatography with electrochemical detection. J Pharm Sci 1993;82:73-6
12. Rohr J, Dufresne J-J. Dihydroergotamine nasal spray for the treatment of migraine attacks: a comparative double-blind crossover study with placebo. Cephalalgia 1985;5 Suppl 3: 142-3
13. Bousser M-G, Loria Y. Efficacy of dihydroergotamine nasal spray in the acute treatment of migraine attacks. Cephalalgia 1985;5 Suppl 3:554-5
14. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994;44:447-53
15. The Dihydroergotamine Nasal Spray Multicenter Investigators. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache 1995;35:177-84
16. Hoffert MJ, Couch JR, Diamond S, et al. Transnasal butorphanol in the treatment of acute migraine. Headache 1995; 35:65-9
17. Shyu WC, Pittman KA, Robinson D, Barbhaiya RH. Multiple-dose phase I study of transnasal butorphanol. Clin Pharmacol Ther 1993;54:34-41
18. Pontiroli AE, Calderara A, Pozza G. Intranasal drug delivery. Potential advantages and limitations from a clinical pharmacokinetic perspective. Clin Pharmacokinet 1989;17:299-307
19. Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995;47:543-8
20. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991;31:291-4
21. Cutler NR, Hussey EK, Sramek JJ, Clements BD, Paulsgrove LA, Busch MA, Donn KH. Oral sumatriptan in pharmacokinetics in the migrainous state. Cephalalgia 1991;11 Suppl 11:222-3
22. Illum L, Davis SS. Intranasal insulin. Clinical pharmacokinetics. Clin Pharmacokinet 1992;23:30-41
23. Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol 1994;47:1253-7